PulmoBioMed Ltd.

PulmoBioMed is a UK-based medical device company headquartered in Newcastle upon Tyne, UK. Our mission is to revolutionise respiratory health by enabling non-invasive deep lung sampling.

Our patented device, PBM-Hale offers a scalable solution for in vitro diagnostics, drug discovery, and public health screening that would otherwise require invasive sampling: Patients simply exhale, clinicians chose what to measure. PBM-Hale, is designed to eliminate the long-standing problem of contamination from the mouth, upper airways, or the environment, to provide a lower lung fluid sample in a sealed vial.

The company and device are registered with the US FDA, with CE marking due Q1 2026. Indicated for the collection of exhaled breath, peer-reviewed research has shown it can be used to quantify lung pathogens and inflammation (cytokines) distinctly from the oral or nasal levels, and without saliva contamination.

Early B2B customers in the USA, UK, Europe, and South Africa are evaluating PBM-Hale as an alternative to bronchoscopy for lung transplant rejection monitoring, diagnosing tuberculosis, and pneumonia.

We are seeking partnerships with IVD assay manufacturers seeking to expand use of their products in lower respiratory tract diagnostics, and distributors with established footprint in local hospital and diagnostic laboratory networks.